This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 4 of 9 for:    hemopatch

Prospective Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Luca Weltert, Cardiochirurgia E.H.
ClinicalTrials.gov Identifier:
NCT02133378
First received: May 6, 2014
Last updated: January 26, 2016
Last verified: January 2016
  Purpose

A new topical hemostatic agent composed of a specifically-formulated porous collagen matrix, coated on one side with a thin protein bonding layer (known as NHS-PEG) has been reported to be extremely effective, in addition to traditional means, in terminating bleeding during cardiac operations with control rates as high as 97,5%. The investigators compared such hemostatic agent (Hemopatch; Baxter Inc, Deerfield, IL) with traditional optimized hemostasis routine.

Following sample size calculation, in a prospective randomized study design, 100 patients will be treated with Hemopatch and 100 patients will receive traditional optimized hemostasis routine (comparison group).

To make the two cohorts as comparable as possible enrollment will be restricted to moderately bleeding vascular anastomosis of Dacron grafts to ascending aorta or moderately bleeding transversal aortotomy.

Study endpoints are the following: rate of successful intraoperative hemostasis (identified by cessation of bleeding in less than 3 minutes from application) and time required for hemostasis; overall postoperative bleeding; rate of transfusion of blood products; rate of surgical revision for bleeding; postoperative morbidity; and intensive care unit stay.


Condition Intervention
Bleeding Device: Hemopatch Behavioral: Traditional Hemostasis Techniques (dry or wet gauze compression or similar)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Randomized Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery.

Resource links provided by NLM:


Further study details as provided by Luca Weltert, Cardiochirurgia E.H.:

Primary Outcome Measures:
  • Percentage of Successful Hemostasis in under 3 minutes [ Time Frame: 3 minutes ]
    Application of Hemopatch or traditional techniques (compression with dry or wet gauze or similar) are considered successful if hemostasis is reached in under 3 minutes


Secondary Outcome Measures:
  • Post Operative Blood Loss [ Time Frame: 6 hours ]
    Blood loss in the first 7 hours postoperatively


Other Outcome Measures:
  • Allogeneic Blood Transfusion [ Time Frame: 4 days ]
    Allogeneic Blood Transfusion in the first 4 days after surgery


Enrollment: 170
Study Start Date: March 2014
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hemopatch
Use of Hemopatch on bleeding spot
Device: Hemopatch
Baxter Hemopatch
Sham Comparator: Control
Traditional techniques hemostasis (dry or wet gauze compression or similar)
Behavioral: Traditional Hemostasis Techniques (dry or wet gauze compression or similar)

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Surgery on Ascending Aorta with Dacron Graft or transverse Aortotomy
  • Moderate bleeding

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02133378

Locations
Italy
European Hospital
Rome, Italy, 00151
Sponsors and Collaborators
Cardiochirurgia E.H.
  More Information

Publications:
Responsible Party: Luca Weltert, Dr. Luca Weltert, Cardiochirurgia E.H.
ClinicalTrials.gov Identifier: NCT02133378     History of Changes
Other Study ID Numbers: 2014-01
Study First Received: May 6, 2014
Last Updated: January 26, 2016

Keywords provided by Luca Weltert, Cardiochirurgia E.H.:
Bleeding
Hemostatic

Additional relevant MeSH terms:
Hemorrhage
Pathologic Processes
Hemostatics
Coagulants

ClinicalTrials.gov processed this record on August 18, 2017